Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis

NCT06779097 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

1564

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

DRUG: Vunakizumab (IL-17A inhibitor)

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.